Biofrontera
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
120 Presidential Way Ste 330, Woburn, Ma...Phone Number
(781) 245-1325Website
www.biofrontera-us.comRevenue
$41.7 MillionStock Symbol
BFRIIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Biofrontera
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Explore more
Biofrontera Org Chart
Get the full picture
Sign in to uncover key details.
DW
Associate Director, Financial Reporting
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Biofrontera your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Biofrontera launches new products
Funding: Get notified immidiatlly once Biofrontera has new funding data
Check out if Biofrontera is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Biofrontera
Earning: See what the market has to say on Biofrontera recently announced quarterly report
Click to see if Biofrontera had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Biofrontera, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Biofrontera has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Biofrontera
Compare insights from companies similar to Biofrontera, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Biofrontera is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Biofrontera is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Biofrontera.
Biofrontera financials insights
Gather financial insights about Biofrontera, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Debt
$6.5M
2025
Private Equity
$11M
Biofrontera Tech Stack
A closer look at the technologies used by Biofrontera
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Earnings
Earnings, Finance
Earnings
Earnings, Finance
Earnings
Earnings, Finance
New Hire
Executive Move
Executive Moves, New Hire
Biofrontera News & Media
Biofrontera (BFRI) Q1 2026 Earnings Transcript
All risks and uncertainties are detailed in and are qualified by the cautionary statements contained in Biofrontera's press releases and SEC filings, including the company's quarterly report on Form 10-Q for the quarter ended March 31, 2026, and the company's annual report on Form 10-K for the year ended December 31, 2025. Biofrontera undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conferenceBiofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
WOBURN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May 28, 2026.Biofrontera Inc. (BFRI) Q1 2026 Earnings Call Transcript
Biofrontera Inc. (BFRI) Q1 2026 Earnings Call May 14, 2026 11:00 AM EDTCompany ParticipantsHermann Lubbert - CEO, President & ChairmanGeorge Jones -...Biofrontera Inc. Reports First Quarter 2026 Financial Results and Provides a Business Update
Woburn, MA, May 14, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three months ended March 31, 2026 and provided a business update.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Biofrontera
Sign Up For FreeTo access detailed company insights
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Amelu... Read More
